Stockscreener 앱 받기
0.65
0.81%
0.0052
시간 외 거래:
.64
-0.01
-1.54%
Pavmed Inc 주식(PAVM)의 최신 뉴스
PAVmed shareholders approve stock issuance and charter amendment - Investing.com India
Lucid Diagnostics Achieves Record-Breaking Quarter with 84% Surge in EsoGuard DNA Test Volume - StockTitan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - Kilgore News Herald
Lucid Inks New Partnership With VITALExam: Stock to Gain? - MSN
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophag - GuruFocus.com
Lucid Gains Extension of Compliance by NASDAQ - Baystreet.ca
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - Marketscreener.com
Lucid Diagnostics Gets Nasdaq Extension to Meet $1 Listing Requirement Through June 2025 - StockTitan
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Eastern Progress Online
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters - GuruFocus.com
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - The Eastern Progress Online
PAVmed stock plunges to 52-week low, touches $0.6 By Investing.com - Investing.com Canada
PAVmed stock plunges to 52-week low, touches $0.6 - Investing.com
Critical Survey: PAVmed (NASDAQ:PAVM) and PolyPid (NASDAQ:PYPD) - Defense World
PAVmed (NASDAQ:PAVM) versus Embecta (NASDAQ:EMBC) Financial Review - Defense World
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuar - GuruFocus.com
Lucid Diagnostics' EsoGuard Shows Breakthrough 85% Compliance Rate in Major Clinical Study - StockTitan
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication (PR Newswire) - Aktiellt
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication - PR Newswire
PAVmed (NASDAQ:PAVM) Price Target Lowered to $19.00 at Ascendiant Capital Markets - Defense World
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - The Eastern Progress Online
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones - Lelezard
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones – Company AnnouncementFT.com - Financial Times
Lucid Diagnostics Secures $21.95M Convertible Note Financing, Extends Cash Runway - StockTitan
Symbol Lookup - GuruFocus.com
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Vi - GuruFocus.com
PAVmed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lucid Diagnostics Provides Business Update and Third Quarter 202 - GuruFocus.com
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test - PR Newswire
PAVmed Q3 2024 Earnings Preview - MSN
Lucid Diagnostics Seeks Medicare Coverage for EsoGuard Test with New Clinical Data - StockTitan
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, D - GuruFocus.com
PAVmed Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
Earnings call: PAVmed reports strategic shifts and Q3 financials - Investing.com
PAVmed Inc. (NASDAQ:PAVM) Q3 2024 Earnings Call Transcript - Insider Monkey
PAVmed Inc. (PAVM) Quarterly 10-Q Report - Quartzy
PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring - Yahoo Finance
PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Reven - GuruFocus.com
PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring By GuruFocus - Investing.com Canada
First Manhattan Co. LLC's Strategic Acquisition of PAVmed Inc Sh - GuruFocus.com
PAVmed Inc Reports Q3 2024 Earnings: Revenue at $996,000, Non-GA - GuruFocus.com
PAVmed Reports Record Revenue and Strategic Restructuring - TipRanks
PAVmed Provides Business Update and Third Quarter 2024 Financial Results - PR Newswire
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 - Kilgore News Herald
PAVMPAVmed Inc. Latest Stock News & Market Updates - StockTitan
Lucid Diagnostics' EsoGuard Revenue Surges 50% YoY, Sets Record Testing Volume in Q3 | PAVM Stock News - StockTitan
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results - PR Newswire
PAVmed's Earnings: A Preview - Benzinga
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication – Company AnnouncementFT.com - Financial Times
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication - PR Newswire
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers - BioSpace
Lucid Diagnostics expands direct contracting for cancer testing - Investing.com
0.25%
0.57%
자본화:
|
볼륨(24시간):